Skip to main content
. 2020 Jan 14;4(1):165–173. doi: 10.1182/bloodadvances.2019000864

Figure 3.

Figure 3.

Clinicopathological associations with uMRD attainment. Five patients with late confirmation of uMRD (2 in PB, 3 in BM) without prior assessment were included. (A) Cumulative incidence of uMRD in the peripheral blood or bone marrow stratified by coadministration of rituximab or not. (B) Cumulative incidence of uMRD in the peripheral blood or bone marrow stratified by complex karyotype or not. (C) Cumulative incidence of uMRD in the peripheral blood or bone marrow stratified by TP53 abnormality or not. (D) Cumulative incidence of uMRD in the peripheral blood or bone marrow stratified by fludarabine refractoriness.